Related Experiment Video
Updated: Aug 7, 2026
23:06
The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
Published on: August 11, 2008
Treatment of multidrug-resistant tuberculosis
1Denver Disease Control Service, Denver Department of Health and Hospitals, Colorado, USA.
The Journal of Hospital Infection
|June 1, 1995
Summary
Multi-drug-resistant tuberculosis (MDR-TB) poses a severe threat, especially to AIDS patients, due to delayed diagnosis and ineffective treatments. Optimal MDR-TB management requires prolonged multi-drug regimens based on drug susceptibility testing.
Area of Science:
- Infectious Diseases
- Pulmonology
- Public Health
Background:
- Multi-drug-resistant tuberculosis (MDR-TB) outbreaks cause significant morbidity and mortality, particularly in patients with Acquired Immunodeficiency Syndrome (AIDS).
- Poor outcomes are linked to delayed diagnosis, slow susceptibility testing, inadequate treatment, and severe immunosuppression.
- Current treatment strategies for MDR-TB are suboptimal, with limited prospective clinical trial data.
Purpose of the Study:
- To review the challenges and current understanding of managing multi-drug-resistant tuberculosis (MDR-TB).
- To highlight treatment considerations and prevention strategies for MDR-TB.
- To identify the need for novel therapeutic agents.
Main Methods:
- Retrospective analysis of MDR-TB patient outcomes.
- Review of treatment regimens and their efficacy.
- Evaluation of prevention strategies including directly observed therapy and infection control.
Main Results:
- In immunocompetent patients, prolonged multi-drug regimens yielded a 56% response rate and a 22% mortality rate.
- Patients with AIDS experienced significantly poorer outcomes and shorter median survival (2-4 months).
- Treatment response correlated with in vitro susceptibility of the patient's Mycobacterium tuberculosis isolates.
Conclusions:
- Optimal MDR-TB treatment involves at least three drugs with documented in vitro susceptibility, administered for a minimum of 24 months.
- Regimens may include ethambutol, pyrazinamide, quinolones, and aminoglycosides; surgery can benefit selected patients.
- Prevention through directly observed therapy and infection control is crucial; development of new drugs is essential for improved efficacy.
More Related Videos
09:57System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
10:24Identification of Potential Anti-TB Candidates: A Step-by-Step Guide to Synthesis, MIC Determination, and Cytotoxicity Assessment in Mammalian Cells
Published on: May 22, 2026
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:29Pulmonary Tuberculosis I
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:31Pulmonary Tuberculosis III
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
01:26Pulmonary Tuberculosis IV
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:23Tuberculosis
Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...